Frank David (Pharmagellan)
Musings on the NVS-GSK oncology tie-up.
At Two-Year Mark, JOBS Act Is Regulation Even A Biotech Can Love
Alex Lash (Xconomy)
An accessible explanation of the impact of JOBS on the biotech IPO market.
First Million-Dollar Drug Near After Prices Double on Dozens of Treatments
Robert Langreth (Blomberg)
Drug Prices Defy Gravity -- Until The Patent Expires
John LaMattina (Forbes)
A pair of "call and answer" pieces.
Autism and the Agitator
Frank Bruni (New York Times)
On Jenny McCarthy and vaccines (can't seem to discuss one without the other, can we?
Patients Benefit from Open Dialogue and Scientifically Accurate Information on Medicines
Stephanie Fischer (of PhRMA, for Global Genes Project blog)
On the FDA's recent guidance about pharma and social media.
A fight against time
Brian Gehring (The Brimarck Tribune).
The first (to my knowledge) patient profile related to the efforts by Martin Shkreli and Retrophin $RTRX to develop RE-024 for the rare pediatric disease PKAN. I post this without any commentary at this time, but anyone familiar with the Sarepta Therapeutics $SRPT story with eteplirsen and Duchenne muscular dystrophy (DMD) will immediately notice the parallels and use of some pages from the same "playbook".
CNBC's Fast Money needs a trader who knows the basics of biotech
Brad Loncar (The Loncar Blog)
Brad succinctly and superbly captures the brick-through-the-TV frustration many of have when watching CNBC coverage of the biotech space.